RenovoRx (RNXT) Projected to Release Earnings on Wednesday

RenovoRx (NASDAQ:RNXT) is anticipated to issue its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.08) per share and revenue of $0.7040 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

RenovoRx (NASDAQ:RNXT) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.47 million. RenovoRx had a negative net margin of 823.98% and a negative return on equity of 135.03%. On average, analysts expect RenovoRx to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

RenovoRx Price Performance

RenovoRx stock opened at $1.04 on Wednesday. The firm has a market cap of $46.85 million, a P/E ratio of -3.15 and a beta of 0.99. The business has a fifty day moving average of $0.91 and a two-hundred day moving average of $0.93. RenovoRx has a twelve month low of $0.70 and a twelve month high of $1.45.

Institutional Investors Weigh In On RenovoRx

Large investors have recently modified their holdings of the business. Bleichroeder LP raised its position in shares of RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after purchasing an additional 61,379 shares during the last quarter. Geode Capital Management LLC grew its position in RenovoRx by 9.9% during the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after purchasing an additional 31,730 shares during the last quarter. Wealthspire Advisors LLC acquired a new position in RenovoRx during the 4th quarter valued at approximately $212,000. Citadel Advisors LLC acquired a new position in RenovoRx during the 3rd quarter valued at approximately $154,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of RenovoRx in the second quarter worth $98,000. Hedge funds and other institutional investors own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

RNXT has been the subject of a number of analyst reports. Wall Street Zen upgraded RenovoRx from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings raised shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of RenovoRx in a report on Wednesday, April 8th. Finally, Ascendiant Capital Markets lifted their price objective on shares of RenovoRx from $13.50 to $14.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.50.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.